CapsoVision (CV) Return on Capital Employed (2025)

CapsoVision's (CV) quarterly Return on Capital Employed came in at 141.65% in Q4 2025, up 20.5% quarter-over-quarter from 178.17% in Q3 2025.

CapsoVision (CV) Return on Capital Employed (2025) Analysis & Trends

CapsoVision has disclosed Return on Capital Employed across 1 years of filings, most recently posting 141.65% for Q4 2025.

Return on Capital Employed for Q4 2025 came in at 141.65%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 141.65% (changed N/A YoY), and the FY2025 annual result was 195.43%, changed N/A from the prior year.
Return on Capital Employed came in at 141.65% for Q4 2025 at CapsoVision, up from 178.17% in the prior quarter.
In the past five years, Return on Capital Employed ranged from a high of 141.65% in Q4 2025 to a low of 227.37% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	9.61%
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	12.24%
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	7.36%
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	9.62%
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	11.13%
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	9.30%
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	10.45%
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	24.24%
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	11.57%
10	CapsoVision	176.55 Mn	166.44 Mn	1.95 Mn	-141.65%

Download Data